Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 4/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27466986 | 0.86 | GRIN1 (0.59) | GRIN1GRIN2B | |
| Hydrochloric Acid SCHEMBL7325272 | 0.85 | MEN1 (0.42) | MEN1KMT2AGRIN1GRIN2BCHRM2 | |
| Hydrochloric Acid SCHEMBL7313723 | 0.85 | GRIN1 (0.58) | GRIN1GRIN2B | |
| SCHEMBL8523461 | 0.84 | LMNA (0.53) | MEN1KMT2AGRIN1GRIN2BCHRM2 | |
| Hydrochloric Acid SCHEMBL7325842 | 0.83 | LMNA (0.51) | MEN1KMT2AGRIN1GRIN2BCHRM2 | |
| SCHEMBL27468416 | 0.82 | DRD2 (0.50) | GRIN1GRIN2BSIGMAR1DRD2 | |
| Hydrochloric Acid SCHEMBL7325377 | 0.80 | LMNA (0.40) | GRIN1LMNADRD2 | |
| Hydrochloric Acid SCHEMBL6139683 | 0.76 | LMNA (0.46) | MEN1KMT2AGRIN1LMNADRD2 | |
| SCHEMBL25317343 | 0.74 | SIGMAR1 (0.38) | SIGMAR1 | |
| SCHEMBL27482620 | 0.73 | SLC18A3 (0.47) | MEN1KMT2ASLC18A3SIGMAR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364033-A1 | COMPOUNDS FOR TREATING VIRUS INFECTIONS | MELETIOS THERAPEUTICS (FR) | 2023-11-16 | — | — | US | disclosed |
| EP-4213822-A1 | COMPOUNDS FOR TREATING VIRUS INFECTIONS | MELETIOS Therapeutics (FR) | 2023-07-26 | — | — | EP | disclosed |
| CN-116437960-A | Compounds for the treatment of viral infections | 梅莱蒂奥斯治疗 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022058533-A1 | COMPOUNDS FOR TREATING VIRUS INFECTIONS | MELETIOS THERAPEUTICS (FR) | 2022-03-24 | — | — | WO | disclosed |
| EP-0917464-A1 | USE OF AMINES TO PRODUCE DRUGS FOR PREVENTING TUMOUR CELL PROLIFERATION | SANOFI (FR) | 1999-05-26 | — | — | EP | disclosed |
| WO-1998004251-A1 | USE OF AMINES TO PRODUCE DRUGS FOR PREVENTING TUMOUR CELL PROLIFERATION | SANOFI (FR) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364033-A1 | COMPOUNDS FOR TREATING VIRUS INFECTIONS | ACE, HAVCR2, FURIN | MEN1 704/4885KMT2A 2884/4885GRIN1 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.